Editorial introduction
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer
Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer
Optimal biopsy strategies for the diagnosis and staging of prostate cancer
The utility of 5-α reductase inhibitors in the prevention and diagnosis of prostate cancer
Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen
Predicting cancer-control outcomes in patients with renal cell carcinoma
Outcomes and follow-up strategies for patients on active surveillance
Dietary intervention strategies to modulate prostate cancer risk and prognosis
Patient selection for focal therapy of localized prostate cancer
Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance
Targeted focal therapy for prostate cancer: a review
Critical appraisal of robotic-assisted radical prostatectomy
Critical appraisal of outcomes following open radical prostatectomy
Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner?
Management of localized prostate cancer in men over 65 years
Novel secondary hormonal therapy in advanced prostate cancer: an update
Complications of androgen deprivation therapy in prostate cancer
Current World Literature